Keith W. Pfeil - Jun 25, 2021 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role
SVP, Chief Financial Officer
Signature
/s/ Kelly G. Huller, Attorney-in-Fact
Stock symbol
GMED
Transactions as of
Jun 25, 2021
Transactions value $
-$646,407
Form type
4
Date filed
6/28/2021, 04:52 PM
Previous filing
May 7, 2021
Next filing
Jul 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Options Exercise $661K +13.3K $49.65 13.3K Jun 25, 2021 Direct
transaction GMED Class A Common Stock Options Exercise $755K +14.2K $53.27 14.2K Jun 25, 2021 Direct
transaction GMED Class A Common Stock Sale -$2.06M -27.5K -100% $75.04 0 Jun 25, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -13.3K -38.06% $0.00 21.7K Jun 25, 2021 Class A Common Stock 13.3K $49.65 Direct F3
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -14.2K -35.42% $0.00 25.8K Jun 25, 2021 Class A Common Stock 14.2K $53.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 These options were granted on September 3, 2019, and vest over a four-year period with one-fourth (1/4) of the options vesting on August 19, 2020 and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F4 These options were granted on January 22, 2020, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2021, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.